Printer Friendly

WATSON PHARMACEUTICALS RE-ACQUIRES LICENSES FOR TWO PROPRIETARY DRUG DELIVERY SYSTEMS-BASED PRODUCTS

 CORONA, Calif., June 21 /PRNewswire/ -- Watson Pharmaceuticals (NASDAQ: WATS) today announced it has re-acquired from a U.S. pharmaceutical company worldwide rights for two products under development which employ Watson's proprietary drug delivery systems (DDS) technology. Terms of the agreement were not disclosed.
 According to Dr. Allen Chao, chief executive officer, the two products are Buprenorphine, a synthetic opiate analgesic utilizing Watson's buccal (between the cheek and gum) DDS technology and Prochlorperazine, an anti-emetic, also employing the company's buccal DDS. Buprenorphine requires additional bioavailability and clinical studies before submission to the FDA while, the company believes, Prochlorperazine requires only a bioavailability study before submission.
 "We have re-acquired the rights to these products to accelerate them through the regulatory approval process," said Chao. "We see opportunities for Buccal Prochlorperazine and especially for the analgesic Buccal Buprenorphine. Watson is actively developing and marketing analgesic products. Furthermore, clinical and marketing studies have led the company to believe that there are substantial market opportunities for a buccal form of Buprenorphine. This method of delivery removes the anxiety and discomfort associated with an injection, currently the only approved method of delivery for Buprenorphine in the United States. We are also pursuing the re- acquisition of other products employing our proprietary DDS to capitalize on what we believe are market opportunities," added Chao.
 Watson Pharmaceuticals manufactures and distributes off-patent pharmaceuticals and is developing advanced drug delivery systems designed to enhance the therapeutic benefits of pharmaceutical compounds.
 -0- 6/21/93
 /CONTACT: Doug Sherk or Stu Brunet, 415-296-7383, or June Filingeri or Miriam Adler, 212-850-5600, all of Morgen-Walke for Watson Pharmaceuticals/
 (WATS)


CO: Watson Pharmaceuticals ST: California IN: MTC SU:

TM-TB -- SF002 -- 3865 06/21/93 06:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 21, 1993
Words:282
Previous Article:NEW O'REILLY RELEASE MAXIMIZES RISC PERFORMANCE
Next Article:IDB TO PARTNER WITH ISRAELI-BASED TELECOMMUNICATIONS PROVIDER; PACT POSITIONS IDB IN RAPIDLY DEREGULATING ISRAELI MARKET
Topics:


Related Articles
WATSON PHARMACEUTICALS ANNOUNCES FDA APPROVAL FOR VERAPIMIL HYDROCHLORIDE TABLET
SCHERER OBTAINS RIGHTS TO NEW DRUG DELIVERY SYSTEMS
HYAL COMPLETES FIRST LICENSING ARRANGEMENT IN AUSTRALIA
DURA PHARMACEUTICALS, INC., DURA DELIVERY SYSTEMS, INC. AND ELAN CORPORATION, PLC. ANNOUNCE BROAD STRATEGIC ALLIANCE
DURA PHARMACEUTICALS SIGNS LICENSING AGREEMENT WITH ELI LILLY TO MARKET TWO ANTI-TUBERCULOSIS PRODUCTS
FUJISAWA TO UTILIZE DURA'S DRY POWDER DRUG DELIVERY SYSTEM IN DEVELOPMENT OF A NEW RESPIRATORY COMPOUND
Cellegy Awarded U.S. Patent For Drug Delivery System; Technology Holds Promise for Delivery of Wider Range of Drugs Through the Skin
Watson Pharmaceuticals Acquires Exclusive Rights to Dilacor XR(R) From Rhone-Poulenc Rorer
Sheffield Pharmaceuticals and Elan Complete Formation of Pulmonary Drug Delivery Collaboration
PowderJect and Prometic Sign Smart Particle(TM) Agreement.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters